Bacteria
Impetigo
search
Impetigo
, NonBullous Impetigo, Streptococcal Impetigo, Staphylococcal Impetigo, Common Impetigo
See Also
Bullous Impetigo
Ecthyma
Epidemiology
Preschool children (age 2-5 years old) most often affected
Most common
Bacteria
l
Skin Infection
in children
Non-
Bullous Impetigo
represents 70% of cases, whereas
Bullous Impetigo
represents the remainder
Highly contagious
Spreads across body with scratching, towels or clothing resulting in satellite lesions (autoinoculation)
Spreads easily in households, daycares and schools
Pathophysiology
Streptococcus Pyogenes
and
Staphylococcus Aureus
normally colonize the nose and pharynx, axilla and perineum
Local
Skin Trauma
allows colonizing
Bacteria
to break through skin barrier and results in localized infection
Causes
Staphylococcus Aureus
Most common cause of Impetigo, esp. in resource rich countries and temperate climates
Spreads via skin to skin contact and fomites (e.g. towels)
Not correlated with nasal carriage of staphyloccus aureus
Group A Streptococcus
(
Streptococcus Pyogenes
)
May also cause Impetigo, especially in warm, humid climates (endemic regions)
Spreads via skin to skin contact and respiratory secretions
Asymptomatic pharyngeal carriers in 3% of adults and 8% of children (up to 50% during school outbreaks)
Predisposing factors
Minor
Skin Trauma
(e.g. abrasions,
Insect Bite
s)
Hot, humid weather
Poor hygiene
Daycare attendence
Over-crowded living conditions
Comorbid conditions (especially
Diabetes Mellitus
)
Malnutrition
Atopic Dermatitis
Hemodialysis
Types
Bullous Impetigo
(less common)
Staphylococcal toxin mediated reaction
Affects only the superficial
Epidermis
NonBullous Impetigo (>70%): Described below
Host response to infection
Primary Impetigo (most common)
Due to direct spread of infection (
Staphylococcus Aureus
and/or
Group A Streptococcus
)
Secondary Impetigo (Common Impetigo)
Related to underlying secondary Impetigo cause
Common predisposing factors (see above)
Diabetes Mellitus
AIDS
Herpes Simplex Virus
Varicella
Insect Bite
s
Symptoms
Pruritus
is often present
Signs
Streptococcal Impetigo
Distribution
Affects face (esp. nares, perioral), extremities and other exposed areas
Characteristics
Onset with 2 mm
Macule
or
Papule
Rapidly evolves into
Vesicle
and erythematous margin
Vesicle
breaks
Leaves erosion with honey colored crust
Full skin thickness lesions occur with
Ecthyma
due to Group A Beta Hemolytic
Streptococcus
Associated findings
Regional Lymphadenopathy
Signs
Staphylococcal Impetigo
See
Bullous Impetigo
(30% of cases)
Similar to Streptococcal Impetigo
Minimal surrounding erythema
Lesion more shallow
Complications
Cellulitis
Poststreptococcal Glomerulonephritis
(PSGN)
Occurs with Streptococcal Impetigo caused by S. pyogenes (the Impetigo strains have minimal nephritogenic potential)
Rare now due to
Staphylococcus Aureus
as the most Common Impetigo cause (previously 1-5% of Impetigo)
PSGN is most commonly associated with
Streptococcal Pharyngitis
(also due to
Streptococcus Pyogenes
)
Not prevented by
Antibiotic
use
Rheumatic Fever
Associated with
Group A Streptococcus
(typically
Pharyngitis
)
Labs
Optional (Impetigo is clinical diagnosis)
Lesion
Gram Stain
reveals
Gram Positive Cocci
Lesion culture indications
Poststreptoccal
Glomerulonephritis
outbreaks
Methicillin
-Resistant Staphylococcal aureus suspected
Differential Diagnosis
Common
Herpes Simplex Virus
(HSV)
Atopic Dermatitis
Contact Dermatitis
Insect Bite
s
Varicella
Scabies
Inflammatory
Superficial Fungal Infection
Cutaneous Candidiasis
Dermatophytosis
(e.g.
Tinea Capitis
)
Uncommon
Acute
Pustular Psoriasis
Acute
Palmoplantar Pustulosis
Primary cutaneous
Listeriosis
(farmers)
Sweet's Syndrome
Pemphigous foliaceus
Ecthyma
Discoid Lupus Erythematosus
(especially childhood)
Zinc Deficiency
(perioral facial rash)
Course
Mild to moderate cases are non-scarring, self limited
Untreated cases heal in 3-6 weeks
Treated cases resolve more quickly
Management
Gene
ral measures
Soap
and water to remove crusts
Infections are self-limited even without
Antibiotic
s
However
Antibiotic
s speed resolution and help to prevent spread to others
Topical therapy (as effective as systemic)
Mupirocin
(
Bactroban
) 2% ointment
Applied three times daily to affected area for 5 days
May be used in age 2 months and older
Broad spectrum coverage against
Group A Streptococcus
,
MSSA
,
MRSA
and some
Gram Negative
s
Retapamulin
(
Altabax
) 1% ointment
Apply twice daily to affected area for 5 days
May be used in age 9 months and older
Treatment area must be <100 cm2 (or <2% total BSA in children)
Bacteriostatic against
Group A Streptococcus
and
MSSA
(but not
MRSA
)
Much more expensive than
Mupirocin
with less coverage
Ozenoxacin (Xepi)
Topical
Quinolone
with minimal systemic absorption and FDA approved for age >2 months
Released in 2017, but discontinued in U.S. in 2025
Available internationally outside the U.S.
Bacteriocidal against
Group A Streptococcus
,
MSSA
,
MRSA
Fusidic Acid 2% cream (Not available in United States)
Apply three times daily to affected area for 5 days
Koning (2002) BMJ 324:203-6 [PubMed]
Systemic Agents
Gene
ral
In most cases, topical agents are preferred
When systemic
Antibiotic
s are used, limit to narrow spectrum (GAS,
MSSA
,
MRSA
) and for 7-10 days
Systemic
Antibiotic
indications
Severe or extensive cases
Unresponsive to topicals after 3-5 days
Outbreaks affecting multiple patients
Preferred systemic agents (for 7-10 days)
Cephalexin
(
Keflex
)
Child: 25-50 mg/kg/day divided three times daily to four times daily
Adult: 250-500 mg orally three to four times daily
Dicloxacillin
Child: 12.5 to 25 mg/kg/day orally divided three times daily to four times daily
Adult: 250-500 mg orally three to four times daily
Staphylococcus
suspected (especially if suspected
MRSA
, for 7-10 days)
Precautions
Review local antibiograms to determine local resistance rates
Given the self-limited nature of Impetigo, consider topical agents only (see above)
Clindamycin
Adult: 300-600 every 6-8 hours
Child: 10-25 mg/kg/day divided every 6 to 8 hours
Doxycycline
Adult (or wt >45 kg): 100 mg orally twice daily
Child (wt <45 kg): 2 mg/kg up to 100 mg orally twice daily
Avoid use under age 8 years old
Trimethoprim-Sulfamethoxazole (
Septra
DS,
Bactrim
DS)
Adult: 1 tab orally twice daily
Child: 8-10 mg/kg/day (of trimethoprim component) orally divided twice daily
AVOID
Topical Disinfectants
(no better than
Placebo
or soap and water, and may cause irritation)
Chlorhexidine
Hexachlorophene (Phisohex)
Povidone-Iodine
Shampoo
offers no benefit
Koning (2002) BMJ 324:203-6 [PubMed]
Prevention
Clean minor injuries with soap and water
Regular
Handwashing
and bathing, including cleaning under
Fingernail
s
Thoroughly wash clothing, towels, bedding and toys with detergents and antiseptics after Impetigo exposure
Avoid contact with infected patients (esp. children)
May
Return to School
, daycare 12-24 hours after starting
Antibiotic
s (or after clinical improvement begins)
Cover active lesions if possible
References
Cydulka in Marx (2002) Rosen's Emergency Med., p. 1639
Swartz in Mandell (2000) Infectious Disease, p. 1037
Cole (2007) Am Fam Physician 75(6):859-68 [PubMed]
Brown (2003) Int J Dermatol 42:251-5 [PubMed]
Hartman-Adams (2014) 90(4): 229-35 [PubMed]
Trang (2026) Am Fam Physician 113(2): 175-80 [PubMed]
Type your search phrase here